Abstract

BackgroundRenal cell carcinoma (RCC) is one of the most common cancers in middle-aged patients. We aimed to establish a new nomogram for predicting cancer-specific survival (CSS) in middle-aged patients with non-metastatic renal cell carcinoma (nmRCC).MethodsThe clinicopathological information of all patients from 2010 to 2018 was downloaded from the SEER database. These patients were randomly assigned to the training set (70%) and validation set (30%). Univariate and multivariate COX regression analyses were used to identify independent risk factors for CSS in middle-aged patients with nmRCC in the training set. Based on these independent risk factors, a new nomogram was constructed to predict 1-, 3-, and 5-year CSS in middle-aged patients with nmRCC. Then, we used the consistency index (C-index), calibration curve, and area under receiver operating curve (AUC) to validate the accuracy and discrimination of the model. Decision curve analysis (DCA) was used to validate the clinical application value of the model.ResultsA total of 27,073 patients were included in the study. These patients were randomly divided into a training set (N = 18,990) and a validation set (N = 8,083). In the training set, univariate and multivariate Cox regression analysis indicated that age, sex, histological tumor grade, T stage, tumor size, and surgical method are independent risk factors for CSS of patients. A new nomogram was constructed to predict patients' 1-, 3-, and 5-year CSS. The C-index of the training set and validation set were 0.818 (95% CI: 0.802-0.834) and 0.802 (95% CI: 0.777-0.827), respectively. The 1 -, 3 -, and 5-year AUC for the training and validation set ranged from 77.7 to 80.0. The calibration curves of the training set and the validation set indicated that the predicted value is highly consistent with the actual observation value, indicating that the model has good accuracy. DCA also suggested that the model has potential clinical application value.ConclusionWe found that independent risk factors for CSS in middle-aged patients with nmRCC were age, sex, histological tumor grade, T stage, tumor size, and surgery. We have constructed a new nomogram to predict the CSS of middle-aged patients with nmRCC. This model has good accuracy and reliability and can assist doctors and patients in clinical decision making.

Highlights

  • In recent years, renal cell carcinoma (RCC) incidence has gradually increased, accounting for 2-3% of adult malignant tumors [1]

  • We found that age (HR 1.05, 95%confidence interval (CI) 1.03-1.06, p < 0.001), sex (HR 0.7, 95%CI 0.59-0.82, p < 0.001), tumor histological grade (HR 1.41, 95%CI 1.34-1.49, p < 0.001), T stage (HR 2.55, 95%CI 2.352.75, p < 0.001), tumor size (HR 1.01, 95%CI 1.01-1.01, p < 0.001), and surgery (HR 1.23, 95%CI 1.1-1.38, p < 0.001) were related to survival prognosis

  • Based on the nomogram we constructed, we developed a web application to predict the cancer-specific survival (CSS) of middle-aged patients with non-metastatic renal cell carcinoma (nmRCC)

Read more

Summary

Introduction

Renal cell carcinoma (RCC) incidence has gradually increased, accounting for 2-3% of adult malignant tumors [1]. The incidence of RCC in the United States is about 9.1 per 100,000, and the mortality rate is 3.5 per 100,000 [2]. It has been reported in the literature that 15% of patients with RCC diagnosed for the first time have developed distant metastases, and another 10-20% of patients with localized RCC eventually develop metastatic RCC [3, 4]. In 2016, there were 6,700 new diagnoses of RCC in the United States, and 14,240 patients died of renal cancer [7]. Renal cell carcinoma (RCC) is one of the most common cancers in middle-aged patients. We aimed to establish a new nomogram for predicting cancer-specific survival (CSS) in middle-aged patients with non-metastatic renal cell carcinoma (nmRCC)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call